Full Press Release Details
Date: February 14, 2013
RedHill Biopharma Announces Date of
Financial Results and Corporate Update
RedHill Biopharma Ltd. (NASDAQ:
RDHL; TASE: RDHL), an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage,
patent-protected, new formulations and combinations of existing drugs, announced that it plans to release its FY 2012 results on
Tuesday, February 19th, 2013.
The Company will host a conference call
and an audio webcast at 09:00am EST on Wednesday, February 20th, 2013.
To participate in the conference call please dial 1-866-966-9439
(domestic U.S., toll free) or +1-631-510-7498 (International) and use access code: 11015754 #.
The conference call will be broadcasted
simultaneously and archived on the Company's website, http://ir.redhillbio.com/. To participate, please access the Company's website
at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The webcast replay
will be available on RedHill's website for 30 days.
About RedHill Biopharma Ltd.:
RedHill Biopharma is an emerging Israeli
biopharmaceutical company focused primarily on the development of late clinical-stage, patent protected, new formulations and combinations
of existing drugs. The Company's current product pipeline includes a once-daily formulation of a leading congestive heart failure
and high blood pressure drug, a once-daily formulation of a leading chemotherapy and radiotherapy-induced nausea and vomiting prevention
drug, an oral thin film formulation of a leading drug for the treatment of acute migraine, a combination therapy for the treatment
of Crohn's disease as well as Multiple Sclerosis (MS) disease, a combination therapy for the treatment of Helicobacter pylori bacteria
causing ulcers, and an encapsulated formulation for bowel preparation ahead of certain gastro procedures. For more information
please visit: www.redhillbio.com.